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Treatment of breast cancer during pregnancy: 
an observational study
Sibylle Loibl, Sileny N Han, Gunter von Minckwitz, Marijke Bontenbal, Alistair Ring, Jerzy Giermek, Tanja Fehm, Kristel Van Calsteren, 
Sabine C Linn, Bettina Schlehe, Mina Mhallem Gziri, Pieter J Westenend, Volkmar Müller, Liesbeth Heyns, Brigitte Rack, Ben Van Calster, 
Nadia Harbeck, Miriam Lenhard, Michael J Halaska, Manfred Kaufmann, Valentina Nekljudova, Frederic Amant
Summary
Background Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether 
treatment for breast cancer during pregnancy is safe for both mother and child.
Methods We recruited patients from seven European countries with a primary diagnosis of breast cancer during 
pregnancy; data were collected retrospectively if the patient was diagnosed before April, 2003 (when the registry 
began), or prospectively thereafter, irrespective of the outcome of pregnancy and the type and timing of treatment. 
The primary endpoint was fetal health for up to 4 weeks after delivery. The registry is ongoing. The study is registered 
with ClinicalTrials.gov, number NCT00196833.
Findings From April, 2003, to December, 2011, 447 patients were registered, 413 of whom had early breast cancer. 
Median age was 33 years (range 22–51). At the time of diagnosis, median gestational age was 24 weeks (range 5–40). 
197 (48%) of 413 women received chemotherapy during pregnancy with a median of four cycles (range one to eight). 
178 received an anthracycline, 15 received cyclophosphamide, methotrexate, and ﬂ uorouracil, and 14 received a taxane. 
Birthweight was aﬀ ected by chemotherapy exposure after adjustment for gestational age (p=0·018), but not by number 
of chemotherapy cycles (p=0·71). No statistical diﬀ erence between the two groups was observed for premature deliveries 
before the 37th week of gestation. 40 (10%) of 386 infants had side-eﬀ ects, malformations, or new-born complications; 
these events were more common in infants born before the 37th week of gestation than they were in infants born in the 
37th week or later (31 [16%] of 191 infants vs nine [5%] of 195 infants; p=0·0002). In infants for whom maternal treatment 
was known, adverse events were more common in those who received chemotherapy in utero compared with those who 
were not exposed (31 [15%] of 203 vs seven [4%] of 170 infants; p=0·00045). Two infants died; both were exposed to 
chemotherapy and delivered prematurely, but both deaths were thought not to be related to treatment. Median disease-
free survival for women with early breast cancer was 70·6 months (95% CI 62·1–105·5) in women starting chemotherapy 
during pregnancy and 94·4 months (lower 95% CI 64·4; upper 95% CI not yet reached) in women starting chemotherapy 
after delivery (unadjusted hazard ratio 1·13 [95% CI 0·76–1·69]; p=0·539).
Interpretation Although our data show that infants exposed to chemotherapy in utero had a lower birthweight at 
gestational age than did those who were unexposed, and had more complications, these diﬀ erences were not clinically 
signiﬁ cant and, since none of the infants was exposed to chemotherapy in the ﬁ rst trimester, were most likely related 
to premature delivery. Delay of cancer treatment did not signiﬁ cantly aﬀ ect disease-free survival for mothers with 
early breast cancer. Because preterm birth was strongly associated with adverse events, a full-term delivery seems to 
be of paramount importance.
Funding BANSS Foundation, Biedenkopf, Germany and the Belgian Cancer Plan, Ministry of Health, Belgium.
Introduction
Breast cancer diagnosed during pregnancy is rare, con-
tributing to less than 1% of breast cancers in Europe.1 The 
incidence of breast cancer during pregnancy is increasing, 
likely due to women in high-income countries having 
children at an increasingly older age, with the probability 
of developing breast can cer increasing with age.2,3 In 
2006, about 57 000 women were diagnosed with breast 
cancer in Germany, of whom only 4% were aged 39 years 
or younger.4 Because of the low incidence of breast cancer 
during pregnancy and despite an increasing number of 
studies, evidence-based management of breast cancer 
during pregnancy is not possible because most infor-
mation is based on small cohorts. In 1999, Berry and 
colleagues5 published a series of 24 patients with breast 
cancer treated during pregnancy using a standardised 
protocol at the MD Anderson Cancer Center (Houston, 
TX, USA), which was updated in 2006.6 This report 
formed the basis for the ﬁ rst international recom-
mendations on breast cancer during pregnancy and was 
the stimulus for a more structured method for the 
collection of data in breast cancer during pregnancy.7
We launched the Breast Cancer During Pregnancy 
Registry in 2003 to systematically investigate breast 
can cer during pregnancy, assessing the outcome of 
mothers and their infants. We aimed to test the 
hypothesis that breast cancer treatment during 
pregnancy is safe for mother and child, and that 
Lancet Oncol 2012; 13: 887–96
Published Online
August 16, 2012
http://dx.doi.org/10.1016/
S1470-2045(12)70261-9
See Comment page 852
German Breast Group, 
Neu-Isenburg, Germany 
(Prof S Loibl MD, 
Prof G von Minckwitz MD, 
V Nekljudova PhD); 
Multidisciplinary Breast Cancer 
Centre, Leuven Cancer Institute 
(S N Han MD, Prof F Amant PhD), 
Gynaecologic Oncology, 
Department of Oncology 
(M Mhallem Gziri MD, 
L Heyns MSc), Katholieke 
Universiteit Leuven, Belgium; 
BOOG/Department of Medical 
Oncology, Erasmus MC-Daniel 
den Hoed Cancer Centre, 
Rotterdam, Netherlands 
(M Bontenbal MD); Brighton and 
Sussex Medical School, Sussex 
Cancer Centre, Royal Sussex 
County Hospital, Brighton, UK 
(A Ring MD); Oncology Centre, 
Institute in Warsaw Breast 
Cancer and Reconstructive 
Surgery Clinic, Warsaw, Poland 
(Prof J Giermek MD); University 
Women Hospital, Tübingen, 
Germany (Prof T Fehm MD); 
Obstetrics (K Van Calsteren PhD), 
Department of Development 
and Regeneration and Leuven 
Cancer Institute 
(B Van Calster PhD), UZ 
Gasthuisberg, Leuven, Belgium; 
BOOG/Department of Medical 
Oncology, Netherlands Cancer 
Institute and Antoni van 
Leeuwenhoek Hospital, 
Amsterdam, Netherlands 
(S C Linn MD); University 
Women Hospital Heidelberg, 
Gemany (B Schlehe MD); BOOG/
Laboratory for Pathology, 
Dordrecht, Netherlands 
(P J Westenend MD); Department 
of Gynaecology, University 
Medical Centre Hamburg-
Eppendorf, Hamburg, Germany 
(Prof V Müller MD); Ludwigs 
Maximilian University, 
Frauenklinik Innenstadt, 
Munich, Germany (B Rack PhD); 
Breast Centre, Department of 
Articles
888 www.thelancet.com/oncology   Vol 13   September 2012
Obstetrics and Gynaecology, 
University of Cologne, 
Germany (Prof N Harbeck MD); 
Department of Gynaecology 
and Obstetrics, Hospital of the 
LMU of Munich, Grosshadern, 
Germany (M Lenhard PhD); 
Department of Obstetrics and 
Gynaecology, Charles 
University in Prague, Czech 
Republic (M J Halaska PhD); and 
J W Goethe University, 
Department of Obstetrics and 
Gynaecology, Frankfurt, 
Germany (Prof M Kaufmann MD)
Correspondence to:
Prof Sibylle Loibl, German Breast 
Group, c/o GBG-Forschungs 
GmbH, Martin-Behaim-Str 12, 
63263 Neu-Isenburg, Germany
sibylle.loibl@
germanbreastgroup.de
For the case report form see 
http://www.germanbreastgroup.
de/pregnancy
For the Belgian international 
online registry see http://www.
cancerinpregnancy.org
pregnant patients with breast cancer should, therefore, 
be treated as similarly as possible to non-pregnant 
patients with breast cancer. A second similar initiative 
that registered patients with all cancers during pregnancy 
was initiated in Belgium.
Methods
Study design and patients
The German Breast Group (GBG) launched a multicentre 
registry cohort study for breast cancer during pregnancy 
in April, 2003, which was expanded to other countries 
(the Netherlands, UK, Poland, Italy, and Czech Republic) 
in April, 2009, via the Breast International Group (BIG) 
and other international collaborations (115 centres). All 
patients diagnosed with breast cancer during pregnancy 
were eligible for registration, independent of outcome of 
the pregnancy and the type and timing of breast cancer 
treatment (no age restrictions). The data were collected 
with a case report form, which is available online. Also, 
Belgian and UK groups were asked to provide data partly 
published.8,9 Patients could be registered retrospectively 
if they were diagnosed before the initiation of the GBG 
registry in (April, 2003) and prospectively if their 
diagnosis was made thereafter. In the same timeframe, 
although independent from the German initiative, an 
international online registry for all cancers diagnosed 
during preg nancy was initiated in Belgium. Both 
observational studies were approved by the ethics 
committees (University of Frankfurt,  Germany, and 
Leuven University, Belgium) and patients had to give 
written informed consent for data and biomaterial 
collection.
The study protocol of the GBG provided a treatment 
algorithm for breast cancer that was dependent on the 
patient’s gestational age. The primary objective of the 
study was the outcome of the infant for up to 4 weeks after 
delivery. Secondary objectives were gestational com pli-
cations of the mother, stage and biological char acteristics 
of breast cancer, breast cancer treatments (systemic 
treatment and type of surgery), diagnostic procedures 
(palpation, ultrasound, mammogram, and MRI), and 
long-term outcome of the infant and the mother.
Weight, height, haematology counts, Apgar scores at 
5 min and 10 min, hair loss, and signs of infection were 
recorded with direct questioning at birth and at 4 weeks 
after birth. All other events were reported as free text at 
the discretion of the reporting physician. Follow-up was 
obtained from annual visits to a physician. Metrics such 
as height, weight, and any abnormalities were obtained. 
Information about the decision-making process (ie, 
induced vs spontaneous abortion or delivery) was not 
collected. Follow-up is ongoing.
Statistical analysis
The main analysis was descriptive. All percentages 
excluded missing values. We used Fisher’s exact test 
(for binary parameters), χ² test (for parameters with 
three or more categories), and Wilcoxon test (for 
continuous parameters) to do between-group com-
parisons. We used analysis of covariance (ANCOVA) to 
explore the eﬀ ect of gestational week and intrauterine 
exposure to chemo therapy on birthweight, and linear 
regression to explore the eﬀ ect of gestational week and 
number of chemo therapy cycles on birthweight. We 
constructed Kaplan-Meier survival curves to estimate 
the median disease-free survival (DFS) and overall 
survival and used a Cox proportional-hazards model to 
estimate the hazard ratio and 95% CI. Two sided 
p values of 0·05 or less were deemed signiﬁ cant. Data 
were collected into an MS SQL Server database. We 
used SAS (version 9.2 under SAS Enterprise Guide 4.3) 
for all statistical analyses.
Role of the funding source
The sponsors of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between April 1, 2003, and Dec 31, 2011, the cutoﬀ  date 
for this analysis, 447 eligible patients were registered Figure 1: Proﬁ le of patient cohort
455 patients registered
8 patients excluded (no data for disease 
    and outcome received)
447 eligible
Information about treatment
         205 chemotherapy during pregnancy
         192 chemotherapy after delivery or interruption
            32 without chemotherapy
            18 missing chemotherapy information
Information about pregnancy outcome
         369 information about pregnancy, treatment, and delivery
            51 abortion or miscarriage
            19 missing information about pregnancy outcome
              8 histological diagnosis at time of delivery
34 patients with distant metastases
      30 primary M1 (having distant metastases at 
            ﬁrst diagnosis)
        4 diagnosis of metastases during pregnancy
Information about treatment
         8 chemotherapy during pregnancy
       21 chemotherapy after delivery
         4 no chemotherapy
          1 unknown
Information about pregnancy outcome
       24 delivery
          8 abortion or miscarriage
          2 missing information
413 patients with early breast cancer
Information about treatment
         197 chemotherapy during pregnancy
                  134 treated after 2003
                    63 treated before 2003
         171 chemotherapy after delivery/interruption
           28 without chemotherapy
           17 missing chemotherapy information
Information about pregnancy outcome
         346 information on pregnancy, therapy, and delivery
            43 abortion or miscarriage
            12 missing information about pregnancy outcome
              8 histological diagnosis at the time of delivery
              4 information on delivery but therapy information 
                  missing
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(ﬁ gure 1). In 299 patients, diagnosis was made after the 
start of the registry and data were collected prospectively. 
A further 148 patients were diagnosed before the start of 
the registry and their data were collected retrospectively. 
The median follow-up for DFS and overall survival for 
the women was 31·5 months (95% CI 21·5–42·3).
Baseline characteristics of participants are shown in 
table 1. The median age of the women was 33 years (range 
22–51) with the median gestational age at diag nosis of 
24 weeks (5–40). 178 (42%) women were diagnosed with 
breast cancer during the second trimester of pregnancy. 
T4 tumours were more common in patients who received 
chemotherapy during pregnancy compared with those 
who had chemotherapy after pregnancy (p=0·0053; 
table 1). We recorded no other signiﬁ cant diﬀ erences 
between these two populations of patients. Diagnosis 
during pregnancy was guided by ultrasound in 83% 
(322 of 387 patients), mammography in 51% (198 of 
387 patients), and MRI in 16% (60 of 387 patients) of 
patients (60 patients with imaging type unknown).
182 (51%) of 358 patients with early breast cancer were 
treated with breast conservation surgery (48% of patients 
All patients 
(N=447)
M0 patients 
(N=413)
M0 patients with 
chemotherapy 
(N=368)
M0 patients with 
chemotherapy during 
pregnancy (N=197)
M0 patients with 
chemotherapy after 
delivery (N=171)
Age (years; median [range]) 33 (22–51) 33 (22–51) 33 (23–51) 33 (25–43) 34 (23–51)
Tumour stage
T1 86 (20%) 83 (21%) 66 (18%) 32 (17%) 34 (20%)
T2 217 (50%) 203 (51%) 186 (52%) 96 (51%) 90 (54%)
T3 92 (21%) 82 (21%) 78 (22%) 40 (21%) 38 (23%)
T4a–c 25 (6%) 23 (6%) 20 (6%) 18 (10%) 2 (1%)
T4d 11 (3%) 9 (2%) 8 (2%) 4 (2%) 4 (2%)
Data missing 16 13 10 7 3
Nodal status
Negative 181 (42%) 176 (44%) 150 (41%) 72 (37%) 78 (46%)
Positive 252 (58%) 229 (57%) 213 (59%) 121 (63%) 92 (54%)
Data missing 14 8 5 4 1
Histological tumour type
Ductal or other 419 (97%) 390 (97%) 351 (98%) 188 (98%) 163 (98%)
Lobular 14 (3%) 11 (3%) 8 (2%) 4 (2%) 4 (2%)
Data missing 14 12 9 5 4
Grading
G1 10 (3%) 10 (3%) 8 (2%) 3 (2%) 5 (3%)
G2 87 (22%) 78 (21%) 73 (22%) 34 (19%) 39 (25%)
G3 296 (75%) 280 (76%) 257 (76%) 143 (79%) 114 (72%)
Data missing 54 45 30 17 13
ER/PgR-status
Negative for both ER or PgR 214 (52%) 203 (53%) 185 (54%) 99 (54%) 86 (54%)
Positive for ER, PgR, or both 197 (48%) 180 (47%) 159 (46%) 86 (47%) 73 (46%)
Data missing 36 30 24 12 12
HER2 status
Negative 226 (64%) 214 (65%) 197 (65%) 101 (64%) 96 (66%)
Positive 126 (36%) 113 (35%) 108 (36%) 58 (37%) 50 (34%)
Data missing 95 86 63 38 25
Triple negative 118 (31%) 115 (33%) 109 (34%) 55 (32%) 54 (37%)
Gestational week at diagnosis (median [range]) 24 (1–40) 24 (1–40) 24 (1–40) 20 (1–36) 30 (1–40)
Trimester at diagnosis
First trimester 81 (19%) 76 (19%) 60 (17%) 31 (16%) 29 (18%)
Second trimester 178 (42%) 170 (43%) 160 (45%) 132 (68%) 28 (17%)
Third trimester 169 (40%) 152 (38%) 137 (38%) 31 (16%) 106 (65%)
Unknown 19 15 11 3 8
Gestational week at chemotherapy start (median) ·· ·· ·· 24 NA
Data are n (%), unless otherwise stated. ER=oestrogen receptors. PgR=progesterone receptors. NA=not applicable. 
Table 1: Baseline characteristics
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[57 of 120] treated before registry inception [April, 2003] 
and 53% of patients [125 of 238] treated thereafter; p=0·37; 
data missing for 55 patients). For the 396 women with 
early breast cancer and known chemotherapy treatment, 
breast conservation surgery was done in 79 (45%) of 
197 patients starting chemotherapy during pregnancy 
(data missing for 23 patients) and in 100 (56%) of 
199 patients who started chemotherapy after delivery  or 
received no chemotherapy (data missing for 21 patients; 
p=0·055).
In total, 1187 chemotherapy cycles were given, 745 (63%) 
of which were given during pregnancy. Chemotherapy 
regimens are summarised in table 2. The patients 
received a median of four cycles (range one to eight) 
during pregnancy. 178 (90%) of the 197 patients who 
received chemo therapy during pregnancy received an 
anthracycline (102 epirubicin, 76 doxorubicin; 10 of the 
vinca alcaloid-based regimens contained an anthra-
cycline); 15 (8%) patients received cyclophosphamide, 
metho trexate, and ﬂ uorouracil during pregnancy (CMF; 
all before April, 2003) and 14 (7%) patients received a 
taxane during pregnancy (nine docetaxel, ﬁ ve paclitaxel), 
of whom ten also received an anthracycline. Overall, 
77 (39%) of 197 patients with early breast cancer received 
a taxane as part of their adjuvant or neoadjuvant 
chemotherapy, but most received the taxane after delivery 
(table 2). Treatment with a taxane-free regimen was more 
common in women whose chemotherapy was started 
during pregnancy compared with those whose 
chemotherapy was started after pregnancy (118 [60%] of 
197 patients vs 81 [47%] of 171 patients; p=0·021). 
Combined docetaxel, doxorubicin, and cyclophosphamide 
and dose-dense sequential epirubicin, paclitaxel, and 
cyclophosphamide were given only after delivery. None of 
the patients received trastuzumab, endocrine therapy, or 
radiotherapy during pregnancy (table 2).
Chemotherapy after delivery 
(N=171)
Chemotherapy during 
pregnancy (N=197*)
A(E)/C 16 (9%) 55 (28%)
FE(A)C 42 (25%) 34 (17%)
AC/EC-taxane 29 (17%) 46 (23%)
FE(A)C-taxane 19 (11%) 19 (10%)
CMF 16 (9%) 11 (6%)
AC/EC-CMF 4 (2%) 4 (2%)
FE(A)C-CMF 0 (··) 1 (1%)
A(E)mono-CMF 3 (2%) 4 (2%)
A(E)mono-taxane 0 (··) 4 (2%)
A(E)mono-taxane-CMF 1 (1%) 0 (··)
A(E)taxane 3 (2%) 0 (··)
A(E)taxane-CMF 1 (1%) 0 (··)
TAC 20 (12%) 0 (··)
dd E-P-C 4 (2%) 0 (··)
TC 1 (1%) 1 (1%)
Vinca alcaloid-based† 0 (··) 13 (7%)
Platinum-containing† 7 (4%) 2 (1%)
Other† 5 (3%) 3 (2%)
A=doxorubicin. C=cyclophosphamide. E=epirubicin. F=ﬂ uorouracil. CMF=cyclophosphamide, methotrexate, 
ﬂ uorouracil. T=docetaxel. P=paclitaxel. dd=dose-dense. Parenthesis mean “or” and solidi are “combined with”—eg  
A(E)/C=doxorubicin or epirubicin combined with cyclophosphamide. Data are n (%). *Not all agents were given during 
the course of pregnancy. †Some of these regimens contained taxanes. 
Table 2: Chemotherapy regimens
All patients 
(N=447)
M0 patients 
(N=413)
M1 patients 
(N=34)
p 
value*
All M0 patients with 
known chemotherapy 
and delivery outcome 
(N=346)
M0 patients with 
chemotherapy 
during pregnancy 
(N=194)
M0 patients with 
chemotherapy after 
delivery or no 
chemotherapy (N=152)
p value†
Abortion 0·039 ·· ·· ··
No 382 (88%) 358 (89%) 24 (75%)
Yes 51 (12%) 43 (11%) 8 (25%)
Unknown 14 12 2
Delivery mode 0·077 0·540
Spontaneous 171 (49%) 165 (50%) 6 (26%) 156 (49%) 85 (48%) 71 (51%)
Operative vaginal delivery 18 (5%) 16 (5%) 2 (9%) 16 (5%) 11 (6%) 5 (4%)
Caesarean section 162 (46%) 147 (45%) 15 (65%) 146 (47%) 83 (47%) 63 (45%)
Unknown 31 30 1 28 15 13
Delivery week (median [range]) 36 (23–42) 37 (23–42) 35 (31–40) 0·022 37 (23–42) 37 (31–42) 36 (23–42) 0·478
Premature delivery
Median birthweight (g [range]) 2770 (1070–4295) 2770 (1070–4295) 2415 (1830–3270) 2770 (1070–4295) 2770 (1260–4050) 2770 (1070–4295)
<37th week 186 (51%) 171 (50%) 15 (65%) 0·196 166 (50%) 89 (47%) 77 (52%) 0·380
<35th week 88 (24%) 78 (23%) 10 (44%) 0·039 77 (23%) 38 (20%) 39 (27%) 0·192
<32nd week 13 (4%) 12 (4%) 1 (4%) 12 (4%) 5 (3%) 7 (5%)
Data missing 14 13 1 11 6 5
Data are n (%) excluding missing data, unless otherwise stated. *p value for diﬀ erence between M0 and M1 patients. †p value for diﬀ erence between patients who received chemotherapy during pregnancy and 
those who received chemotherapy after delivery or not at all. 
Table 3: Obstetrical outcome
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Women diagnosed with distant metastases were more 
likely to have a discontinuation of pregnancy during the 
ﬁ rst trimester (miscarriage or abortion) than were 
women who were diagnosed without distant metastases 
(p=0·039, table 3). Pregnancy was discontinued in 18 
(13%) of 144 patients before 2003 (data missing for four 
patients) and in 33 (11%) of 289  patients after 2003 (data 
missing for ten patients). We recorded no statistically 
signiﬁ cant diﬀ erence in the rates of premature delivery—
before the 37th week of gestation—between those who 
were recruited before 2003 and those who were recruited 
thereafter (56% vs 48%; p=0·15). We recorded no 
signiﬁ cant diﬀ erence in the frequency of premature 
delivery between patients with or without distant 
metastases or between patients given or not given 
chemotherapy during pregnancy (table 2, ﬁ gure 2).
In total, participants gave birth to 386 liveborn babies 
(374 patients continued with pregnancy after diagnosis, 
eight patients were diagnosed at birth, seven women had 
twins, three babies were stillbirths). Information about 
chemotherapy was missing for 13 women, thus 373 new-
born babies were available for the comparison with 
(n=203) or without (n=170) chemo therapy during 
pregnancy (both the early stage and metastatic patients). 
Birthweight of infants exposed to chemo therapy in utero 
(median 2765 g [range 1260–4050]) was much the same as 
those without exposure (median 2758 g [1070–4295]) 
without adjustment for gestational age. Median weight 
4 weeks after delivery in infants exposed to chemotherapy 
in utero was 3590 g (1795–9190) compared with 3375 g 
[2500–5365] in infants without such exposure. After 
adjustment for gestational age, birthweight at delivery was 
aﬀ ected by chemotherapy exposure (ANCOVA test 
p=0·018), but not by number of chemotherapy cycles 
(linear regression p=0·71). Birth weight was less than the 
10th percentile in 15 infants (9% of 175 infants) exposed to 
chemotherapy and in ﬁ ve infants (4%) of 139 infants not 
exposed to chemotherapy (p=0·10; ﬁ gure 2, appendix). 
Median birthweight was not diﬀ erent when analysed by 
exposure to type of anthracycline (epirubicin 2735 g 
[1270–3970] and doxorubicin 2810 g [1260–4050]; p=0·23). 
Median birthweight of the 14 infants exposed to taxanes in 
utero (2713 g [1435–3800]) did not diﬀ er from the 
birthweight of all other babies. We recorded no signiﬁ cant 
diﬀ erence in the frequency of intrauterine growth 
restriction or retardation between fetuses exposed to 
chemotherapy and those without exposure (p=0·069; 
table 4).
We recorded no diﬀ erences between babies who 
were exposed to any chemotherapy in utero and those 
who were not in height, Apgar scores, haemoglobin 
concentration, leucocyte counts, thrombocyte counts, 
and alopecia, at the time of birth as well as at 4 weeks 
after delivery. Nor did we record a diﬀ erence in the 
proportion of infants (for whom we had data) not 
discharged with their mother in these two populations 
(34% [50 of 147] patients vs 41% [47 of 116]; p=0·30).
Overall, we recorded side-eﬀ ects, malformations, or 
newborn complications (hereafter referred to as events) in 
40 (10%) of 386 liveborn infants; events were more 
common in infants born before the 37th week of gestation 
than they were in infants born in the 37th week or later 
(31 [16%] of 191 infants vs nine [5%] of 195 infants; 
p=0·0002). Of the 373 infants for when we have infor-
mation on maternal treatment, events were more common 
in infants exposed to chemotherapy than for infants not 
exposed [31 [15%] of 203 infants vs seven [4%] of 170 infants; 
p=0·00045; ﬁ gure 3). Two infants died; both were exposed 
Figure 2: Median birthweight, by exposure to chemotherapy in utero and week of delivery
N=373 (203 with chemotherapy exposure in utero, 170 without). (A) The lines show median birthweight and the 
bars show number of births. (B) Box-plots show median birthweight in the study population, with bars showing 
IQRs; lines show 10th and 90th percentile birthweight (dashed lines for girls and solid line for boys) for 
pregnancies without cancer involvement in the general population (data from reference 10).
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to chemotherapy and were delivered prematurely 
(ﬁ gure 3). One of these infant’s death was related to a 
diagnosis of trisomy 18 (Edwards’ syndrome); the other 
infant (who died from necrotising enterocolitis) was 
exposed to two cycles of ﬂ uorouracil, epirubicin, and 
cyclophos phamide and weighed 1895 g at delivery in the 
31st week of gestation (80th percentile). Both deaths were 
deemed to be unrelated to chemotherapy exposure. Malfor-
mations were reported in nine (2%) of 386 infants (eight in 
infants exposed to chemotherapy). Five events (four after 
exposure to chemotherapy) were reported beyond 4 weeks 
after delivery: night terrors, acute respiratory distress 
syndrome (ARDS; in two infants), speech impairment 
measured at 6 years old, and motor neuropathy.
65 (19%) of 343 women with early breast cancer—for 
whom data were available for obstetrical complications 
and systemic therapy—had side-eﬀ ects (obstetrical or 
non-obstetrical), of which the occurrence was more 
common in women who received chemotherapy during 
pregnancy (46 [27%] of 179 women) than it was in those 
who did not (17 [10%] of 164 women; p=0·0001). 
Symptoms of preterm delivery including preterm labour 
and premature rupture of the membrane (PROM), were 
signiﬁ cantly higher in women receiving chemotherapy 
during preg nancy compared to those who did not (14 vs 
three [both PROM and preterm labour were reported in 
one patient], p=0·012). Typical obstetrical complications 
(including three stillbirths, one in the chemotherapy 
exposed group) were observed in the group that received 
chemo therapy during pregnancy although most 
No chemotherapy during 
pregnancy (N=164)
Chemotherapy during 
pregnancy (N=179)
p value
Any obstetrical complication
No 149 (91%) 148 (83%) 0·027
Yes 15 (9%) 31 (17%)
Gestational diabetes
No 163 (99%) 177 (99%) 1·00
Yes 1 (1%) 2 (1%)
Pre-eclampsia
No 163 (99%) 177 (99%) 1·00
Yes 1 (1%) 2 (1%)
Hypertension
No 164 (100%) 178 (99%) 1·00
Yes 0 (··) 1 (1%)
Oligohydramnios
No 164 (100%) 176 (98%) 0·249
Yes 0 (··) 3 (2%)
Cervical insuﬃ  ciency
No 164 (100%) 176 (98%) 0·249
Yes 0 (··) 3 (2%)
Placenta insuﬃ  ciency
No 164 (100%) 177 (99%) 0·499
Yes 0 (··) 2 (1%)
Placenta haematoma
No 164 (100%) 178 (99%) 1·00
Yes 0 (··) 1 (1%)
Solution placentae
No 164 (100%) 178 (99%) 1·00
Yes 0 (··) 1 (1%)
Bleeding
No 163 (99%) 175 (98%) 0·374
Yes 1 (1%) 4 (2%)
Vasa praevia
No 164 (100%) 179 (100%) NA
Congenital abnormality (pregnancy termination)
No 164 (100%) 179 (100%) NA
Intrauterine growth restriction
No 163 (99%) 172 (96%) 0·069
Yes 1 (1%) 7 (4%)
(Continues in next column)
No chemotherapy during 
pregnancy (N=164)
Chemotherapy during 
pregnancy (N=179)
p value
(Continued from previous column)
Chorioamnionitis
No 163 (99%) 179 (100%) 0·478
Yes 1 (1%) 0 (··)
Spontaneous abortion (included in pregnancy interruptions)
No 160 (98%) 179 (100%) 0·051
Yes 4 (2%) 0 (··)
Spontaneous abortion of one twin
No 164 (100%) 178 (99%) 1·00
Yes 0 (··) 1 (1%)
Premature labour
No 161 (98%) 169 (94%) 0·090
Yes 3 (2%) 10 (6%)
Premature rupture of the membrane
No 164 (100%) 174 (97%) 0·062
Yes 0 (··) 5 (3%)
Fetal 
distress
No 163 (99%) 177 (99%) 1·00
Yes 1 (1%) 2 (1%)
Stillbirth
No 162 (99%) 178 (99%) 0·608
Yes 2 (1%) 1 (1%)
Pyelonephritis
No 164 (100%) 179 (100%) NA
Cholestasis
No 163 (99%) 179 (100%) 0·478
Yes 1 (1%) 0 (··)
Pruritus
No 163 (99%) 179 (100%) 0·478
Yes 1 (1%) 0 (··)
Data are number of women (%). NA=not applicable. *Data was not available for 
35 women who did not have chemotherapy during pregnancy and for 18 women 
who had chemotherapy during pregnancy. 
Table 4: Obstetrical complications in women with early breast cancer 
with and without chemotherapy during pregnancy (n=343)*
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complications do not show a signiﬁ cant diﬀ erence 
between the two groups (table 4).
The time from diagnosis to start of chemotherapy was 
longer when the decision was taken to start chemotherapy 
after delivery (median 6 weeks [range 0–39] compared with 
median 4 weeks [0–19] when chemo therapy was started 
before delivery; p<0·0001). Overall, 26 (6% of 413) women 
diagnosed with breast cancer before the 28th week of 
gestation delayed chemo therapy to after delivery 
(appendix). In patients with early breast cancer, median 
DFS was 76·3 months (95% CI 64·8–101·3) and the 
median overall survival is not yet reached. The median 
DFS was 70·6 months (95% CI 62·1–105·5) in women 
starting chemotherapy during pregnancy and 94·4 months 
(lower 95% CI 64·4; upper 95% CI not yet reached) in 
women starting chemotherapy after delivery (un adjusted 
hazard ratio 1·13 [95% CI 0·76–1·69]; p=0·539). After 
stratifying for tumour stage and nodal status the log-rank 
p value was as follows: DFS 0·4644; overall survival 0·892. 
We recorded no signiﬁ cant diﬀ erence between patients 
with early breast cancer who started chemotherapy during 
pregnancy and those who started chemotherapy after 
delivery in DFS (estimated 3-year DFS 70·2% [95% CI 
60·8–77·7] vs 74·3% [65·0–81·5]; p=0·537) or overall 
survival (estimated 3-year overall survival 84·9% 
[76·9–90·3] vs 87·4% [79·3–92·5]; p=0·221; ﬁ gure 4). In 
the group of women receiving chemotherapy during 
pregnancy the estimated 5-year DFS was 61·1% 
(50·6–69·9). In the group of women receiving 
chemotherapy after delivery or an interruption, estimated 
5-year DFS was 64·4% (54·2–72·8). Estimated 5-year 
overall survival was 77% (67·1–84·3) in the group of 
women receiving chemotherapy during pregnancy. In the 
group of women receiving chemotherapy after delivery or 
interruption, the estimated 5-year overall survival was 
82·4% (73·1–88·8).
Regression analysis of prognostic variables (age, 
T stage, nodal status, hormone receptor status) and 
application of chemotherapy during pregnancy con-
ﬁ rmed that tumour stage and nodal status, but not 
chemotherapy application during pregnancy signiﬁ cantly 
aﬀ ected DFS and overall survival (table 5).
Discussion
We recorded more neonatal and obstetrical events in 
patients treated with chemotherapy during pregnancy 
than we did in patients who received no chemotherapy 
during pregnancy. Infants exposed to chemotherapy 
during pregnancy had a lower birthweight. 
In the general population, about 10–15% of infants are 
born preterm, which is generally deﬁ ned as before 
completing the 37th week of gestation.11,12 In our study 
population, 50% of women with breast cancer delivered 
preterm, with 23% before the 35th week of gestation. 
However, this proportion of premature deliveries is lower 
than previously reported in all cancers in another 
European pregnancy population.9 In our study population, 
preterm deliveries were more common if the decision 
was taken to start chemotherapy after delivery, although 
most patients reported no additional obstetrical 
complications. In the group who received chemotherapy 
during pregnancy, the pro portion of preterm deliveries 
Figure 3: Adverse events in newborn babies up to 4 weeks after delivery
Respiratory distress combines the following events: continuous positive airway pressure, mild acute respiratory distress syndrome, wet lung. NICU=neonatal 
intensive care unit. proBNP=pro-brain natriuretic peptide. *Baby died.
22 delivery before 37th week 
      of gestation
      3  neutropenia 
      2  anaemia
      1  neonatal jaundice
      1 sepsis
      1 small for gestational age
      1 hypercalciuria
      1 necrotising enterocolitis*
      1 admission to NICU
      1 patent foramen ovale and 
         complex heart or lung problems
      1  patent foramen ovale
      2  cerebral bleeding 
      3 respiratory distress syndrome
      4 malformations
          1 trisomy 18*
          1 rectal atresia 
          1 polydactylia
          1 craniosynostosis
9 delivery in or after the 37th week 
    of gestation
    1 neutropenia 
    1 small for gestational age
    1 high serum concentrations of 
        proBNP
    1 pulmonal artery stenosis
    1  aspiration pneumonia and 
       patent foramen ovale
    1  increased muscle tension
    3 malformation
       1 asymmetric head
       1 polydactyly
       1  möbius syndrome
31 with chemotherapy
9 delivery before 37th week of 
    gestation
    1 hypoglycaemia (M1)
    1 anaemia, gastroenteritis, patent 
       ductus arteriosus
    3  respiratory distress syndrome 
       (1 M1)
    2 neonatal jaundice
    1  grade one cystic lesion brain
    1 malformation (hypospadia, 
       agenesis of ﬁfth ﬁnger) 
0 delivery in or after the 37th week 
    of gestation
7 without chemotherapy
2 unknown treatment
40 complications reported up to 4 weeks after delivery
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was higher than expected because treatment until the 
completion of the 35th week of pregnancy is advised to 
allow for a pause in treatment before delivery.13 However, 
we recorded a non-signiﬁ cant decrease in the number of 
preterm deliveries. This ﬁ nding might be explained by an 
increased awareness among reporting physicians of the 
possibility to give chemotherapy during pregnancy, due 
to the advertisement of the registry and the inclusion of a 
therapy algorithm into the study protocol and guidelines 
published by the investigator.
Morbidity and mortality in newborn babies is directly 
related to gestational age at delivery,13,14 which is an 
important clinical message because the decision to deliver 
the fetus preterm is often taken without medical indication. 
By contrast with other studies, our ﬁ ndings show that 
infants exposed to chemotherapy in utero had a lower 
birthweight at the same gestational age than did infants 
not exposed to chemotherapy, a ﬁ nding that was not 
aﬀ ected by the amount of chemotherapy given and one 
that we believe is clinically irrelevant (because such low 
birthweight would not aﬀ ect an otherwise healthy baby).9 
More complications were reported in the group of 
infants exposed to chemotherapy than in the group not 
exposed to chemotherapy. However, most complications 
were reported in babies who were delivered prematurely, 
irrespective of exposure to chemotherapy. The com-
plications recorded were mostly related to premature 
delivery or malfor mations rather than to chemotherapy 
exposure (none of the children was exposed to chemo-
therapy during the ﬁ rst trimester and malformations can 
occur only during that time). In German quality control 
statistics,11 morbidity in preterm infants is about 9%.12 The 
proportion of malformations in this study is not diﬀ erent 
from the general population.12 Data from previous studies 
suggest that long-term morbidity does not increase if a 
fetus is exposed to chemotherapy in utero compared with 
fetuses who do not have this exposure (panel).15,16 
Although the placenta ﬁ lters cytotoxic agents, important 
variations in trans placental passage among drugs have 
been seen in animal models.17,18 In our study, preterm 
labour or PROM were more common when chemotherapy 
was given during pregnancy with out resulting in more 
preterm deliveries. There are several reasons for this 
ﬁ nding, including physical or psychological stress, 
infections, or an unknown under lying mechanism of the 
cytotoxic agent itself.19 Oxidative stress, which is one of 
the proposed pathophysiological mechanism of pre-
eclampsia, can also be induced by cytotoxic agents.20 
However, the frequency of pre-eclampsia did not increase 
when chemotherapy was given during pregnancy. The 
seemingly high rate of caesarean sections might be 
explained by the number of preterm deliveries and the 
recommendation to deliver before the 35th week of 
gestation, as per guidelines in some countries (eg, 
Germany). The overall caesarean section rate in Germany 
is 30% and rises to more than 50% in high-risk subgroups, 
which is higher than in Belgium or the Netherlands.
Patients who received chemotherapy during pregnancy 
were more likely to have presented at an advanced stage of 
disease than were women who received chemo therapy 
after pregnancy, and were more often treated with 
mastectomy. Tumour grading, hormone receptor status, 
and HER2 status, which show breast cancer biology, were 
much the same between the two groups (exposure to 
chemotherapy during pregnancy vs no exposure). 
However, there seemed to be a higher rate of patients with 
triple-negative, HER2-positive, and grade 3 tumours in our 
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Figure 4: Disease free (A) and overall (B) survival curves for patients with early breast cancer
Patients were censored at the date of last follow-up.
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cohort compared with data for breast cancer in women 
younger than 41 years reported from a single institution.21 
None of our immunohisto chemical data were centrally 
conﬁ rmed.22 DFS in our study is in line with previously 
reported results in young women23 and is much longer 
than that reported in a US case series.24 Survival was not 
statistically diﬀ erent in the two groups of patients who 
received chemotherapy during pregnancy or thereafter, 
indicating that chemotherapy given during pregnancy is 
eﬀ ective despite an altered pharmacokinetic proﬁ le of the 
agents important for breast cancer treatment during 
pregnancy.25,26 Moreover, the adjusted survival analyses 
indicate that women who received chemotherapy during 
pregnancy might have a better survival outcome. However, 
the data should not be over interpreted and certainly do not 
suggest that initiation of treatment should be delayed. 
When chemotherapy was started during preg nancy, 
patients were less likely to receive a taxane or a standard 
chemotherapy regimen.27 Most guidelines for breast cancer 
do not recommend taxanes during pregnancy.8,11,26 
However, the reported complications of the infants if 
taxanes were given during pregnancy did not diﬀ er from 
those of other cytotoxic agents. Data for baboon and 
human models show that taxanes are hardly detectable in 
the fetus.17,28,29 Furthemore, taxanes add eﬃ  cacy 
independent of nodal status and are proposed as part of 
adjuvant or neoadjuvant treatment even during 
pregnancy.10,26,30,31 However, examination of the outcome of 
patients treated with or without taxanes is beyond the 
scope of this study.
We are doing a matched-pair analysis on a subset of 
these patients treated with modern-type chemotherapy to 
reveal the prognosis of breast cancer during pregnancy if 
treated according to actual guidelines compared with 
non-pregnant women.
We did not include patients with a diagnosis of breast 
cancer within 1 year after the end of pregnancy because 
we wanted to address speciﬁ c clinical challenges related 
to the exposure of treatment to the pregnant woman and 
the fetus. Breast cancer diagnosed within the year after 
delivery has been reported to be more aggressive than 
disease not temporally related to pregnancy, but can be 
treated according to standard recommendations.1
Our study has several strengths and limitations. 
The main strength is the descriptive information about 
the obstetric outcome of a large cohort of patients from 
diﬀ erent countries in a joint eﬀ ort that used a stand-
ardised case report form. Most patients were recruited 
from Germany, Belgium, and the Netherlands, where 
treatment strategies are much the same. Some Belgian 
and UK patients were included in a previously published 
report.8,9 However, most cases were reported prospectively, 
with birthweight, height, hair loss, blood count, and 
Apgar scores captured directly, whereas any other 
observations were reported with free text. In view of the 
multicentric and observational nature of the study, 
missing data were unavoidable, especially for the 
follow-up period, and we cannot exclude the possibility 
that there might be a reporting bias in favour of the 
group unexposed to chemotherapy in utero (children 
who were exposed might have been monitored more 
closely than those who were not). Therefore, we need to 
interpret the data in relation to malformations or 
morbidities reported for all deliveries in the general 
population. With 50 000 newly diagnosed breast cancers 
a year in Germany, and an incidence of breast cancers 
diagnosed during pregnancy of 1%, at least 500 should be 
reported, but fewer are documented per year in Germany. 
A further limitation to our study is that the tumour 
characteristics were not balanced between women 
receiving chemotherapy during pregnancy and after 
delivery. However, we compensated for this diﬀ er ence by 
doing an adjusted analysis. Follow-up was short and not 
Disease-free survival Overall survival
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Chemotherapy during pregnancy
No 1 1
Yes 0·784 (0·504–1·22) 0·278 0·864 (0·454–1·64) 0·656
Age (years) 0·979 (0·929–1·03) 0·411 0·953 (0·887–1·02) 0·183
Tumour stage  
T1–3 1 1
T4 5·66 (3·10–10·4) <0·0001 4·44 (2·16–9·14) <0·0001
Nodal status
N0 1 1
N+ 2·75 (1·60–4·74) <0·0001 6·57 (2·28–18·9) <0·0001
Hormone receptor status
ER/PgR negative 1 1
ER/PgR positive 0·652 (0·415–1·02) 0·064 0·593 (0·314–1·12) 0·106
ER=oestrogen receptors. PgR=progesterone receptors. 
Table 5: Multivariate analysis for disease-free and overall survival
Panel: Research in context
Systematic review
We searched PubMed using the terms “breast cancer” and “pregnancy”. We restricted our 
search to studies written in English and published between November, 2010, and April, 
2012. We identiﬁ ed 36 studies dealing with diagnos, treatment, or survival of 
pregnancy-associated breast cancer, which also included women diagnosed with breast 
cancer up to 1 year after delivery. Only 10 publications were based on individual patient 
cohorts with a size of 22–99 patients. Most recommendations for the treatment of breast 
cancer during pregnancy are based on small cohort studies or heterogeneous groups and 
lack comparison with breast cancer patients not treated with systemic therapy during 
pregnancy.
Interpretation
On the basis of our ﬁ ndings from this large cohort of patients with breast cancer, and if our 
ﬁ ndings are substantiated by other studies, breast cancer during pregnancy could be 
treated as it is in non-pregnant women without putting fetal and maternal outcome at 
substantially increased risk. We did, however, record more obstetrical and paediatric events 
in the group treated with chemotherapy during pregnancy, which emphasises the 
importance of a full-term delivery.
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complete, but we will continue to collect data. We did not 
collect information about concomitant and supportive 
drug treatment. Long-term eﬀ ects such as cardiac 
assessments were not captured in a systematic way but 
long-term data are being collected continuously to 
improve the follow-up data for the children.
This large data collection provides a better 
understanding of breast cancer during pregnancy. The 
stage of disease and obstetrical health aﬀ ects treatment 
decision during pregnancy and the outcome of the 
infants. Interactions are numerous and cannot yet 
completely be explained, but data collection is ongoing 
and should eventually help to understand the complexity 
even better. Overall, prospective observational studies 
should increase the level of available evidence and should 
improve treatment recommendations.32
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